Greenwich LifeSciences, Inc.
GLSI
$16.80
$0.422.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -15.15% | -21.45% | -6.63% | -93.52% | -84.25% |
| Total Depreciation and Amortization | -100.00% | -75.00% | -50.00% | -25.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -26.32% | -17.06% | -6.20% | 324.83% | 284.89% |
| Change in Net Operating Assets | 109.66% | -12.32% | -36.02% | 196.24% | 11.07% |
| Cash from Operations | -46.85% | -74.65% | -36.43% | -13.51% | -25.33% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 314.17% | 350.14% | 174.65% | 54.82% | 43.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 314.17% | 350.14% | 174.65% | 54.82% | 43.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 240.28% | 381.40% | 172.00% | 39.32% | -10.23% |